University of Ljubljana Faculty of Pharmacy, Department of Pharmaceutical Chemistry, SI-1000 Ljubljana Slovenia.
Novartis, Global Drug Development, Technical Research & Development Biologics, Drug Product Development, Formulation Development Lek Pharmaceuticals d.d. SI-1000 Ljubljana, Slovenia.
Acta Pharm. 2024 Sep 14;74(3):479-493. doi: 10.2478/acph-2024-0022. Print 2024 Sep 1.
The formulation of biopharmaceutical drugs is designed to eliminate chemical instabilities, increase conformational and colloidal stability of proteins, and optimize interfacial stability. Among the various excipients involved, buffer composition plays a pivotal role. However, conventional buffers like histidine and phosphate buffers may not always be the optimal choice for all monoclonal antibodies (mAbs). In this study, we investigated the effects of several alternative buffer systems on seven different mAbs, exploring various combinations of ionic strengths, concentrations of the main buffer component, mAb concentrations, and stress conditions. Protein stability was assessed by analyzing soluble aggregate formation through size exclusion chromatography. At low protein concentrations, protein instability after temperature stress was exclusively observed in the bis-TRIS/ glucuronate buffer. Conversely, freeze-thaw stress led to a significant increase in aggregate formation in tested formulations, highlighting the efficacy of several alternative buffers, particularly arginine/ citrate, in preserving protein stability. Under temperature stress, the introduction of arginine to histidine buffer systems provided additional stabilization, while the addition of lysine resulted in protein destabilization. Similarly, the incorporation of arginine into histi-dine/HCl buffer further enhanced protein stability during freeze--thaw cycles. At high protein concentrations, the histidine/citrate buffer emerged as one of the most optimal choices for addressing temperature and light-induced stress. The efficacy of histidine buffers in combating light stress might be attributed to the light-absorbing properties of histidine molecules. Our findings demonstrate that the development of biopharmaceutical formulations should not be confined to conventional buffer systems, as numerous alternative options exhibit comparable or even superior performance.
生物制药制剂的配方旨在消除化学不稳定性,增加蛋白质的构象和胶体稳定性,并优化界面稳定性。在涉及的各种赋形剂中,缓冲剂组成起着关键作用。然而,对于所有单克隆抗体(mAbs)来说,传统的缓冲剂(如组氨酸和磷酸盐缓冲剂)并不总是最佳选择。在这项研究中,我们研究了几种替代缓冲系统对七种不同 mAbs 的影响,探索了离子强度、主缓冲成分浓度、mAb 浓度和应激条件的各种组合。通过尺寸排阻色谱法分析可溶性聚集体的形成来评估蛋白质稳定性。在低蛋白浓度下,仅在双三羟甲基氨基甲烷/葡萄糖酸盐缓冲液中观察到温度应激后的蛋白质不稳定性。相反,冻融应激导致测试配方中聚集体形成显著增加,突出了几种替代缓冲剂(特别是精氨酸/柠檬酸盐)在保持蛋白质稳定性方面的功效。在温度应激下,将精氨酸引入组氨酸缓冲体系提供了额外的稳定性,而赖氨酸的添加则导致蛋白质失稳。同样,将精氨酸引入组氨酸/HCl 缓冲液中在冻融循环中进一步增强了蛋白质稳定性。在高蛋白浓度下,组氨酸/柠檬酸盐缓冲液成为应对温度和光诱导应激的最佳选择之一。组氨酸缓冲剂在对抗光应激方面的功效可能归因于组氨酸分子的光吸收特性。我们的研究结果表明,生物制药制剂的开发不应局限于传统的缓冲系统,因为许多替代方案具有相当或甚至更好的性能。